Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence.
Schizophrenia
antipsychotics
bipolar disorder
cannabidiol
major depressive disorder
nutraceuticals
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
30
06
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
The endocannabinoid (eCB) system disruption has been suggested to underpin the development of psychosis, fueling the search for novel, better-tolerated antipsychotic agents that target the eCB system. Among these, palmitoylethanolamide (PEA), an N-acylethanolamine (AE) with neuroprotective, anti-inflammatory, and analgesic properties, has drawn attention for its antipsychotic potential. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at reappraising all clinical and preclinical studies investigating the biobehavioral role of PEA in psychosis. Overall, 13 studies were eligible for data extraction (11 human, 2 animal). Observational studies investigating PEA tone in psychosis patients converged on the evidence for increased PEA plasma (6 human) and central nervous system (CNS; 1 human) levels, as a potential early compensatory response to illness and its severity, that seems to be lost in the longer-term (CNS; 1 human), opening to the possibility of exogenously supplementing it to sustain control of the disorder. Consistently, PEA oral supplementation reduced negative psychotic and manic symptoms among psychosis patients, with no serious adverse events (3 human). No PEA changes emerged in either preclinical psychosis model (2 animal) studied. Evidence supports PEA signaling as a potential psychosis biomarker, also indicating a therapeutic role of its supplementation in the disorder. https://doi.org/10.17605/OSF.IO/AFMTK.
Identifiants
pubmed: 37533892
doi: 10.3389/fpsyt.2023.1231710
pmc: PMC10390736
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1231710Informations de copyright
Copyright © 2023 Bortoletto, Piscitelli, Candolo, Bhattacharyya, Balestrieri and Colizzi.
Déclaration de conflit d'intérêts
MC has been a consultant/advisor to GW Pharma Limited, F. Hoffmann-La Roche Limited, and GW Pharma Italy SRL, outside of this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Diet Suppl. 2023;20(3):505-530
pubmed: 34842030
Neurotoxicology. 2019 Sep;74:282-298
pubmed: 31412258
Schizophr Bull. 2019 Jun 18;45(4):742-751
pubmed: 30169868
Nutrients. 2021 Apr 18;13(4):
pubmed: 33919499
Front Psychiatry. 2022 Oct 28;13:1038122
pubmed: 36387000
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Schizophr Res. 2021 Aug;234:4-23
pubmed: 32336581
Psychiatry Res. 2022 Oct;316:114737
pubmed: 35917650
Transl Psychiatry. 2012 Mar 20;2:e94
pubmed: 22832859
Mol Psychiatry. 2021 Nov;26(11):6269-6276
pubmed: 34002020
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
Int J Mol Sci. 2021 May 18;22(10):
pubmed: 34069940
Psychopharmacology (Berl). 2009 Nov;206(4):551-61
pubmed: 19529920
Biomedicines. 2022 Jan 24;10(2):
pubmed: 35203453
Schizophr Bull. 2009 May;35(3):482-90
pubmed: 19329560
JAMA Psychiatry. 2018 Nov 1;75(11):1107-1117
pubmed: 30167644
Br J Psychiatry. 2010 Feb;196(2):92-5
pubmed: 20118450
Br J Pharmacol. 2017 Jun;174(11):1349-1365
pubmed: 27539936
Int J Mol Sci. 2020 Dec 15;21(24):
pubmed: 33333772
Br J Pharmacol. 2016 Apr;173(7):1154-62
pubmed: 25598150
Psychol Med. 2020 Aug;50(11):1862-1871
pubmed: 31422779
Front Psychiatry. 2023 Feb 06;14:1144943
pubmed: 36815189
World J Biol Psychiatry. 2019 Feb;20(2):117-125
pubmed: 29521179
Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018
pubmed: 31054246
Annu Rev Dev Psychol. 2022 Dec;4(1):423-445
pubmed: 36712999
Pharmacol Res. 2021 Feb;164:105357
pubmed: 33285233
Addict Biol. 2022 Nov;27(6):e13233
pubmed: 36301212
Schizophr Res. 2013 Aug;148(1-3):145-50
pubmed: 23800614
CNS Neurol Disord Drug Targets. 2017;16(6):705-713
pubmed: 28325153
J Neuroinflammation. 2019 Dec 26;16(1):274
pubmed: 31878942
Lancet Psychiatry. 2015 Mar;2(3):258-270
pubmed: 26359903
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3312-25
pubmed: 23108549
Int J Clin Pract. 2007 Dec;61(12):1979-88
pubmed: 17997804
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Neuropsychopharmacology. 2004 Nov;29(11):2108-14
pubmed: 15354183
Hist Psychiatry. 1992 Dec;3(12):499-29
pubmed: 11612918
Eur Neuropsychopharmacol. 2014 Jan;24(1):51-64
pubmed: 24309088
Neuropharmacology. 2019 Mar 1;146:212-221
pubmed: 30496751
Br J Psychiatry. 2003 Nov;183:427-35; discussion 436
pubmed: 14594918
Psychiatry Clin Neurosci. 2022 Oct;76(10):505-511
pubmed: 35737597
Brain Sci. 2022 Jan 12;12(1):
pubmed: 35053844
Neuroreport. 1999 Jun 3;10(8):1665-9
pubmed: 10501554
World J Biol Psychiatry. 2023 Apr;24(4):314-320
pubmed: 35950574
Evid Rep Technol Assess (Summ). 2002 Mar;(47):1-11
pubmed: 11979732
FEBS Lett. 2001 Oct 12;506(3):253-6
pubmed: 11602256
Front Psychiatry. 2021 Feb 04;12:616415
pubmed: 33613341
Psychol Med. 2016 Jan;46(1):27-45
pubmed: 26370602
Compr Psychiatry. 2000 Jan-Feb;41(1):13-8
pubmed: 10646613
Arch Gen Psychiatry. 2007 Jan;64(1):19-28
pubmed: 17199051
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Nat Rev Neurol. 2009 Jun;5(6):299-300
pubmed: 19498428
Neurosci Biobehav Rev. 2016 May;64:359-81
pubmed: 26987641
Mol Neurobiol. 2013 Oct;48(2):340-52
pubmed: 23813098
Psychiatry Res. 2020 Feb 21;286:112890
pubmed: 32126328
Med Sci Monit. 2021 Aug 23;27:e934475
pubmed: 34421116
Psychopharmacology (Berl). 2020 Apr;237(4):1121-1130
pubmed: 31915861
J Psychopharmacol. 2015 Feb;29(2):97-115
pubmed: 25586400
Neurosci Biobehav Rev. 2010 May;34(6):897-921
pubmed: 19954751
Am J Psychiatry. 2018 Mar 1;175(3):225-231
pubmed: 29241357